A defucosylated anti-PD-L1 monoclonal antibody 13-mG_{2a-f} exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma

Junko Takei\textsuperscript{a,b}, Tomokazu Ohishi\textsuperscript{c}, Mika K. Kaneko\textsuperscript{a}, Hiroyuki Harada\textsuperscript{b}, Manabu Kawada\textsuperscript{c}, Yukinari Kato\textsuperscript{a,d,*}

\textsuperscript{a} Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan
\textsuperscript{b} Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
\textsuperscript{c} Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu-shi, Shizuoka, 410-0301, Japan
\textsuperscript{d} New Industry Creation Hatchery Center, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan

\textsuperscript{a} Corresponding author. New Industry Creation Hatchery Center, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
E-mail address: yukinarikato@med.tohoku.ac.jp (Y. Kato).

1. Introduction

Programmed cell death ligand-1 (PD-L1) is a type I transmembrane glycoprotein expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. A strong correlation has been reported between PD-L1 expression in tumor cells and negative prognosis in cancer patients. Previously, we established an anti-PD-L1 monoclonal antibody (mAb), L\textsubscript{1-Mab-13} (IgG\textsubscript{1}, kappa), by immunizing mice with PD-L1-overexpressing CHO-K1 cells. L\textsubscript{1-Mab-13} specifically reacts with endogenous PD-L1 in lung cancer cell lines in flow cytometry and Western blot applications, and stains a plasma membrane-like pattern in lung cancer tissues via immunohistochemical analysis. In this study, we investigated whether L\textsubscript{1-Mab-13} reacts with oral cancer cell lines and exerts antitumor activities. Because L\textsubscript{1-Mab-13} lacks antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), we first converted the subclass of L\textsubscript{1-Mab-13} from IgG\textsubscript{1} into IgG\textsubscript{2a} (13-mG\textsubscript{2a}) and further produced a defucosylated version (13-mG\textsubscript{2a-f}) using FUT8-deficient ExpiCHO-S (BINDS-09) cells. Defucosylation of 13-mG\textsubscript{2a-f} was confirmed using fucose-binding lectins, such as \textit{Aleuria aurantia} and \textit{Pholiota squarrosa} lectins. The dissociation constants \((K\textsubscript{d})\) for 13-mG\textsubscript{2a-f} in SAS and HSC-2 oral cancer cells were determined via flow cytometry to be \(2.8 \times 10^{-9}\) M and \(4.8 \times 10^{-9}\) M, respectively, indicating that 13-mG\textsubscript{2a-f} possesses extremely high binding affinity. In vitro analysis demonstrated that 13-mG\textsubscript{2a-f} showed moderate ADCC and CDC activities against SAS and HSC-2 oral cancer cells. In vivo analysis revealed that 13-mG\textsubscript{2a-f} significantly reduced tumor development in SAS and HSC-2 xenografts in comparison to control mouse IgG, even after injection seven days post-tumor inoculation. Taken together, these data demonstrate that treatment with 13-mG\textsubscript{2a-f} may represent a useful therapy for patients with PD-L1-expressing oral cancers.

Keywords: PD-L1 Monoclonal antibody ADCC CDC Antitumor activity Oral cancer

Article info

ABSTRACT

Programmed cell death ligand-1 (PD-L1) is a type I transmembrane glycoprotein expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. A strong correlation has been reported between PD-L1 expression in tumor cells and negative prognosis in cancer patients. Previously, we established an anti-PD-L1 monoclonal antibody (mAb), L\textsubscript{1-Mab-13} (IgG\textsubscript{1}, kappa), by immunizing mice with PD-L1-overexpressing CHO-K1 cells. L\textsubscript{1-Mab-13} specifically reacts with endogenous PD-L1 in lung cancer cell lines in flow cytometry and Western blot applications, and stains a plasma membrane-like pattern in lung cancer tissues via immunohistochemical analysis. In this study, we investigated whether L\textsubscript{1-Mab-13} reacts with oral cancer cell lines and exerts antitumor activities. Because L\textsubscript{1-Mab-13} lacks antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), we first converted the subclass of L\textsubscript{1-Mab-13} from IgG\textsubscript{1} into IgG\textsubscript{2a} (13-mG\textsubscript{2a}) and further produced a defucosylated version (13-mG\textsubscript{2a-f}) using FUT8-deficient ExpiCHO-S (BINDS-09) cells. Defucosylation of 13-mG\textsubscript{2a-f} was confirmed using fucose-binding lectins, such as \textit{Aleuria aurantia} and \textit{Pholiota squarrosa} lectins. The dissociation constants \((K\textsubscript{d})\) for 13-mG\textsubscript{2a-f} in SAS and HSC-2 oral cancer cells were determined via flow cytometry to be \(2.8 \times 10^{-9}\) M and \(4.8 \times 10^{-9}\) M, respectively, indicating that 13-mG\textsubscript{2a-f} possesses extremely high binding affinity. In vitro analysis demonstrated that 13-mG\textsubscript{2a-f} showed moderate ADCC and CDC activities against SAS and HSC-2 oral cancer cells. In vivo analysis revealed that 13-mG\textsubscript{2a-f} significantly reduced tumor development in SAS and HSC-2 xenografts in comparison to control mouse IgG, even after injection seven days post-tumor inoculation. Taken together, these data demonstrate that treatment with 13-mG\textsubscript{2a-f} may represent a useful therapy for patients with PD-L1-expressing oral cancers.

Received 28 July 2020; Accepted 10 August 2020

https://doi.org/10.1016/j.bbrep.2020.100801

© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
primary drug of choice, and it is usually combined with 5-fluorouracil and docetaxel [21,22]. Other anticancer agents, such as paclitaxel, methotrexate, and carboplatin can be also used for OSCCs [23], but effective molecular targeting drugs, including antibody therapies, are lacking.

PD-L1 has been utilized not only as a molecular marker of anti-PD-1 therapy, but also as a molecular target for antibody therapy. Anti-PD-L1 mAbs, such as atezolizumab, durvalumab, and avelumab has been used for patients with advanced head and neck squamous cell carcinoma (HNSCC) [24]. In 45%–87% of OSCC cases, cancer cells were PD-L1 positive, depending on the cut-off value for positivity and whether cytoplasmic staining was included as positive [24]. Anti-PD-L1 mAbs have been mainly used for PD1/PD-L1 blockade, but antitumor activities by antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against oral cancers have not been investigated.

In our previous study, we developed a novel anti-human PD-L1 antibody, L1Mab-13 (mouse IgG1, kappa), which is useful for flow cytometry, Western blot, and immunohistochemical analysis [25]. In this study, we converted IgG1 subclass L1Mab-13 into IgG2a subclass 13-mG2a-f, and further produced a defucosylated version, 13-mG2a-f-, using FUT8-deficient ExpiCHO-S cells (BINDS-09) [26]. We then investigated whether 13-mG2a-f exhibited ADCC, CDC, and antitumor activities against oral cancers.

2. Materials and methods

2.1. Cell lines

CHO-K1 was obtained from the American Type Culture Collection (ATCC, Manassas, VA). CHO/PD-L1 was previously established [25]. Oral squamous carcinoma cell lines, including SAS (tongue) and HSC-2 (oral cavity), were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB, Osaka, Japan). CHO-K1 and CHO/PD-L1 were cultured in RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan). SAS and HSC-2 were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Nacalai Tesque, Inc., Kyoto, Japan). CHO-K1 and CHO/PD-L1 were subcultured in RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan). The medium is supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA, USA), 100 units/mL of penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B (Nacalai Tesque, Inc.) at 37 ºC in a humidified atmosphere containing 5% CO2.

2.2. Antibodies

Anti-PD-L1 mAb L1Mab-13 (mouse IgG1, kappa) was developed as previously described [25]. To generate 13-mG2a-f, appropriate VH cDNA of mouse L1Mab-13 and Cμ of mouse IgG2a were subcloned into pCAG-Ble vector (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and Vλ and Cλ cDNAs of L1Mab-13 were subcloned into pCAG-Neo vector (FUJIFILM Wako Pure Chemical Corporation). The
vectors were transfected into BINDS-09 (FUT8-deficient ExpiCHO-S cells) using the ExpiCHO Expression System [26]. 13-mG$_{2a}$-f was purified using Protein G-Sepharose (GE Healthcare Bio-Sciences, Pittsburgh, PA). Mouse IgG was purchased from Sigma-Aldrich Corp. (St. Louis, MO).

2.3. Flow cytometry

Cells were harvested by brief exposure to 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (EDTA; Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), cells were treated with primary mAbs for 30 min at 4 °C and subsequently with Alexa Fluor 488-conjugated anti-mouse IgG (1:1000; Cell Signaling Technology, Inc., Danvers, MA, USA). Fluorescence data were collected using an EC800 Cell Analyzer (Sony Corp., Tokyo, Japan).

2.4. Determination of the binding affinity

Cells were suspended in 100 μL of serially diluted mAbs (0.3 ng/mL - 5 μg/mL), followed by the addition of Alexa Fluor 488-conjugated anti-mouse IgG, and fluorescence data were collected using an EC800 Cell Analyzer (Sony Corp.). The dissociation constant ($K_D$) was calculated by fitting binding isotherms to built-in one-site binding models in GraphPad PRISM 6 (GraphPad Software, Inc., La Jolla, CA, USA).

2.5. Enzyme-linked immunosorbent assay (ELISA)

L$_1$Mab-13 and 13-mG$_{2a}$-f were immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific Inc.) at 1 μg/mL for 30 min. After blocking using SuperBlock buffer (Thermo Fisher Scientific Inc.) containing 0.5 mM CaCl$_2$, the plates were incubated with biotin-labeled lectins, such as *Aleuria aurantia* lectin (AAL, fucose binder; Vector Laboratories, Burlingame, CA, USA) [27], *Pholiota squarrosa* lectin (PhoSL, core fucose binder; J-OIL MILLS, Inc., Tokyo, Japan) [28], and Concanavalin A (ConA, mannose binder; Vector Laboratories) [29], followed by 1:3000 diluted peroxidase-conjugated streptavidin (Agilent Technologies, Santa Clarra, CA, USA). The enzymatic reaction was produced using a 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific Inc.). Optical density was measured at 655 nm using an iMark microplate reader (Bio-Rad Laboratories, Inc., Berkeley, CA, USA).

2.6. Animals

All animal experiments were performed in accordance with relevant guidelines and regulations to minimize animal suffering and distress in the laboratory. Animal studies for ADCC and antitumor activity were approved by the institutional committee for experiments of the Institute of Microbial Chemistry (Permit number: 2020–007). Mice were monitored for health and weight every 2 or 4 days. Experiment duration was 3 weeks. A bodyweight loss exceeding 25% and a maximum tumor size exceeding 3000 mm$^3$ were identified as humane endpoints. Mice were

---

**Fig. 2.** Determination of the binding affinity of anti-PD-L1 mAbs for oral cancer cells using flow cytometry. (A) SAS cells were suspended in 100 μL of serially diluted mAbs (0.3 ng/mL - 5 μg/mL), followed by the addition of Alexa Fluor 488-conjugated anti-mouse IgG, and fluorescence data were collected. (B) HSC-2 cells were suspended in 100 μL of serially diluted mAbs (0.3 ng/mL - 5 μg/mL), followed by the addition of Alexa Fluor 488-conjugated anti-mouse IgG, and fluorescence data were collected.

---
with 10% FBS and used as effector cells. Target cells were labeled with water. Splenocytes were washed with DMEM and resuspended in DMEM. Erythrocytes were lysed with a 10-sec exposure to ice-cold distilled water. Six 6-week-old female BALB/c nude mice were purchased from Charles River (Kanagawa, Japan). After euthanization by cervical dislocation, spleens were removed aseptically and single-cell suspension was obtained by using forceps. Spleens were homogenized in a buffer containing 0.5% Triton X-100, 10 mM Tris-HCl (pH 7.4), and 10 mM of EDTA. The death was verified by respiration arrest and cardiac arrest.

2.7. ADCC

Six 6-week-old female BALB/c nude mice were purchased from Charles River (Kanagawa, Japan). After euthanization by cervical dislocation, spleens were removed aseptically and single-cell suspensions were obtained by using forceps. Spleens were homogenized in a buffer containing 0.5% Triton X-100, 10 mM Tris-HCl (pH 7.4), and 10 mM of EDTA. The death was verified by respiration arrest and cardiac arrest.

2.8. CDC

To assess cell viability, cells were labeled with 10-μg/mL Calcein AM (Thermo Fisher Scientific, Inc.) and resuspended in the same medium. The cells (2 × 10^4 cells/well) were plated in 96-well plates and mixed with rabbit complement (final dilution 1:10; Low-Tox-M Rabbit Complement; Cedarlane Laboratories, Hornby, Ontario, Canada), anti-PD-L1 antibodies, or control IgG (mouse IgG2a, Sigma-Aldrich Corp.). After a 6.5-h incubation, the Calcein AM release of supernatant from each well was measured. Fluorescence intensity was determined as described in the ADCC part above.

2.9. Antitumor activity of 13-mG2a-f in the xenografts of oral cancers

Thirty-two 6-week-old female BALB/c nude mice were purchased from Charles River (Kanagawa, Japan) and used at 7 weeks of age. SAS and HSC-2 cells (0.3 mL of 1.33 × 10^6 cells/mL in DMEM) were mixed with 0.5 mL BD Matrigel Matrix Growth Factor Reduced (BD Biosciences, San Jose, CA, USA). 100 μL of this suspension (5 × 10^6 cells) was injected subcutaneously into the left flank. After day 8, 100 μg of 13-mG2a-f and control mouse IgG (Sigma-Aldrich Corp.) in 100 μL PBS was injected intraperitoneally (i.p.) into treated and control mice, respectively. Additional antibodies were then injected on days 14 and 21. Twenty-three days after cell implantation, all mice were euthanized by cervical dislocation, and tumor diameters and volumes were determined as previously described [30].

2.10. Statistical analyses

All data were expressed as mean ± SEM. Statistical analysis used ANOVA and subsequently Sidak’s multiple comparisons test for tumor volume and mouse weight, or Welch’s t-test for ADCC/CDC and tumor weight using GraphPad Prism 7 (GraphPad Software, Inc.). P < 0.05 was adopted as a level of statistical significance.

3. Results

3.1. Development and characterization of 13-mG2a-f, a core-fucose-deficient mouse IgG2a-type anti-PD-L1 antibody

As mouse IgG2a possesses high ADCC and CDC activities [31], we first developed a mouse IgG2a version of L1-Mab-13 (mouse IgG1) by subcloning appropriate V_H constant of L1-Mab-13 and C_H of mouse IgG2a into pCAG-Neo vector. This IgG2a-type of L1-Mab-13 is henceforth referred to as 13-mG2a. We additionally produced a core-fucose-deficient type of 13-mG2a, henceforth referred to as 13-mG2a-f. The binding affinity of 13-mG2a-f with CHO-K1 cells expressing PD-L1 (CHO/PD-L1) and in OSCC cell lines (SAS and HSC-2) using flow cytometry. Both L1-Mab-13 and 13-mG2a-f reacted with CHO/PD-L1 cells (Fig. 1A), but not with CHO-K1 cells (Fig. 1B). Both mAbs also reacted with SAS cells (Fig. 1C) and HSC-2 cells (Fig. 1D), indicating that 13-mG2a-f demonstrated high sensitivity and specificity for PD-L1.

We conducted a kinetic analysis of the interactions of L1-Mab-13 and 13-mG2a-f with SAS and HSC-2 oral cancer cell lines using flow cytometry. The dissociation constant (K_D) for L1-Mab-13 in SAS cells was determined to be 4.1 × 10^{-9} M (Fig. 2A). In contrast, the K_D for 13-mG2a-f in SAS cells was 2.8 × 10^{-9} M. The binding affinity of 13-mG2a-f in SAS cells was 1.5-fold higher than that of L1-Mab-13. Likewise, the K_D for L1-Mab-13 against HSC-2 cells was 8.8 × 10^{-9} M (Fig. 2B). By contrast, the K_D for 13-mG2a-f in HSC-2 cells was 4.8 × 10^{-9} M. The
The binding affinity of 13-mG$_{2a}$-f in HSC-2 cells was 1.8-fold higher than that of L$_1$Mab-13. The binding affinity of 13-mG$_{2a}$-f in SAS cells was 1.7-fold higher than that in HSC-2 cells.

Defucosylation of 13-mG$_{2a}$-f was confirmed using lectins such as AAL (which binds to fucose) and PhoSL (which binds to core fucose). ConA (which binds to mannose) was used as a positive control. Both L$_1$Mab-13 and 13-mG$_{2a}$-f were detected using ConA (Fig. 3A). L$_1$Mab-13, but not 13-mG$_{2a}$-f, was detected using AAL (Fig. 3B) and PhoSL (Fig. 3C), demonstrating that 13-mG$_{2a}$-f was defucosylated.

### 3.2. ADCC and CDC activities of 13-mG$_{2a}$-f in oral cancer cell lines

Because the mouse IgG$_1$ subclass L$_1$Mab-13 does not possess ADCC or CDC activities, we created a mouse IgG$_2a$ subclass mAb, and further defucosylated it to enhance those activities. In this study, we examined whether the developed 13-mG$_{2a}$-f induced ADCC and CDC in PD-L1-expressing oral cancer cell lines, such as SAS and HSC-2 cells. 13-mG$_{2a}$-f exhibited higher ADCC (17% cytotoxicity) in SAS cells compared with that of control mouse IgG$_{2a}$ treatment (6.6% cytotoxicity; *P* < 0.05) (Fig. 4A). Similarly, 13-mG$_{2a}$-f exhibited higher ADCC (8.0% cytotoxicity) in HSC-2 cells compared with that of control mouse IgG$_{2a}$ treatment (2.5% cytotoxicity; *P* < 0.01) (Fig. 4A).

Furthermore, 13-mG$_{2a}$-f exhibited higher CDC activity (27% cytotoxicity) in SAS cells compared with control mouse IgG$_{2a}$ treatment (7.3% cytotoxicity; *P* < 0.01; Fig. 4B). Similarly, 13-mG$_{2a}$-f exhibited higher CDC activity (15% cytotoxicity) in HSC-2 cells compared with control mouse IgG$_{2a}$ treatment (4.1% cytotoxicity; *P* < 0.01; Fig. 4B). Although ADCC/CDC activities of 13-mG$_{2a}$-f in oral cancer cells are not outstanding, it remained to be seen whether 13-mG$_{2a}$-f may exert antitumor activity against oral cancer cells in vivo.

### 3.3. Antitumor activities of 13-mG$_{2a}$-f in the mouse xenografts of SAS oral cancer cells

In the SAS xenograft models, tumor formation in 16 SAS-injected mice was observed after eight days. These 16 SAS tumor-bearing mice were then divided into a 13-mG$_{2a}$-f-treated group and a control group. On days 8, 14, and 21 after SAS cell injections into the mice, 13-mG$_{2a}$-f (100 μg) and control mouse IgG (100 μg) were injected i.p. into the mice. Tumor formation was observed in mice in both treated and control groups. Tumor volume was measured on days 8, 14, 17, 21, and 23 after SAS cell injection. 13-mG$_{2a}$-f-treated mice showed significantly reduced tumor development on day 17 (*P* < 0.01), day 21 (*P* < 0.01), and day 23 (*P* < 0.01) in comparison to IgG-treated control mice (Fig. 5A). Tumor volume reduction by 13-mG$_{2a}$-f treatment was 51% on day 23. Tumors from 13-mG$_{2a}$-f-treated mice weighed significantly less than tumors from IgG-treated control mice (41% reduction, *P* < 0.05; Fig. 5B). Resected tumors on day 23 are depicted (Fig. 5C). Total body weights did not significantly differ between the two groups (data not shown). These results indicate that 13-mG$_{2a}$-f reduced the growth of SAS xenografts effectively, even when 13-mG$_{2a}$-f was injected eight days post-SAS cell injections in mice.
3.4. Antitumor activities of 13-mG2a-f

In this study, we investigated whether anti-PD-L1 mAbs are advantageous for the treatment of oral cancers by ADCC/CDC activities, rather than by neutralization of PD-L1/PD1 interaction, as human PD-L1 does not react with mouse PD-1. We had previously developed a sensitive and specific anti-PD-L1 mAb, L1Mab-13 [25], but were unable to investigate antitumor activity as the IgG1 subclass does not possess ADCC/CDC activities. Therefore, we converted L1Mab-13 into an IgG2a subclass antibody, and increased ADCC activity via defucosylation. We demonstrated that 13-mG2a-f exerts ADCC/CDC activities in vitro (Fig. 4), and antitumor activities against oral cancer xenografts in vivo (Figs. 5 and 6). Importantly, 13-mG2a-f efficaciously reduced the growth of SAS xenografts (Fig. 5) and HSC-2 xenografts (Fig. 6), even when 13-mG2a-f was injected eight days after cell implantations into the mice. However, SAS and HSC-2 tumor volume reduction on day 23 by 13-mG2a-f treatment only reached 51% and 57%, respectively, indicating that anti-PD-L1 therapy might not be sufficient for solo treatment of most oral cancers. One potential reason for this weak antitumor activity is low ADCC
activity (Fig. 4A) and CDC activity (Fig. 4B) of 13-mG and 47-mG subclass (PcMab-47) into a mouse IgG activity (Fig. 4A) and CDC activity (Fig. 4B) of 13-mG and 47-mG anti-HER2 mAb (clone H.

In another animal experiments.

We recently developed a sensitive and specific mAb against EGFR (clone EMab-17, mouse IgG2a), and examined its ADCC/CDC and anti-
tumor activities against SAS and HSC-2 xenografts [30]. In another recent study, HER2 was shown to be expressed in oral cancers, and an anti-HER2 mAb (clone H2-Mab-19, mouse IgG2b) showed antitumor activity against SAS and HSC-2 xenografts [33]. Further, we previously investigated whether PODXL may be a therapeutic target in OSCC using anti-PODXL mAbs [32]. We converted an anti-PODXL mAb of IgG1 subclass (PcMab-47) into a mouse IgG1 type mAb (47-mG1) to increase ADCC. We developed 47-mG2a, a core fucose-deficient variant of 47-mG2a, to increase its ADCC. In vivo analysis demonstrated that 47-mG2a, but not 47-mG2b, exerted antitumor activity in SAS and HSC-2 xenograft models at a dose of 100 μg/mouse/week administered three times. Although both 47-mG2a and 47-mG2b exhibited antitumor activity in HSC-2 xenograft models at a dose of 500 μg/mouse/week administered twice, 47-mG2a also demonstrated higher antitumor activity than 47-mG2b, indicating that a core fucose-deficient anti-PODXL mAb could be profitable for antibody-based therapy against PODXL-expressing OSCCs.

Targeting multiple targets, such as PODXL, EGFR, HER2, and PD-L1 may be needed for effective therapy to cure oral cancers. Another important goal is to target cancer-specific antigens using a cancer-specific mAb (CasMab). We previously established CasMab against PDPPN, which is expressed in many cancers, including oral cancers [34]. In xenograft models with HSC-2 cells, a mouse-human chimeric mAb, chLpMab-23, exerted antitumor activity using human natural killer cells, indicating that chLpMab-23 may be advantageous for antibody therapy against PDPPN-expressing oral cancers [35]. In the future, cancer-specific anti-PD-L1 mAbs may also be developed that can reduce the adverse effects of traditional antibody therapy.

Funding

This research was supported in part by Japan Agency for Medical Research and Development (AMED) under Grant Numbers: JP20am0401013 (Y.K.), JP20am0101078 (Y.K.), and JP20ae0101028 (Y.K.).

Acknowledgments

We thank Ms. Saori Handa and Mr. Yu Komatsu (Department of Antibody Drug Development, Tohoku University Graduate School of Medicine) for technical assistance of in vitro experiments, and Ms. Akiko Harakawa (Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation) for technical assistance of animal experiments.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi. org/10.1016/j.bbrep.2020.100801.

References


Biochemistry and Biophysics Reports 24 (2020) 100801


